President Donald Trump launched TrumpRx.gov Thursday, a new website promising “the world’s lowest prices” on dozens of popular prescription medications through direct discounts from major pharmaceutical companies. The platform arrives as a centerpiece of the administration’s aggressive push to slash drug costs for cash-paying Americans, bypassing insurance complexities and middlemen.
Speaking at a White House event flanked by Health and Human Services Secretary Robert F. Kennedy Jr., Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz and Pfizer CEO Dr. Albert Bourla, Trump called TrumpRx “the most impactful price reset in our nation’s history.” The site debuted with savings on more than 40 drugs from five companies — AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer — with 11 more manufacturers joining soon.
Users visit TrumpRx.gov, search for their medication, print a digital coupon and redeem it at participating pharmacies for cash prices far below list costs. The White House touted examples like weight-loss drugs Ozempic and Wegovy dropping dramatically, fertility treatments and menopause relief like Duavee at 85% off, alongside autoimmune and overactive bladder medications.
How TrumpRx works: Cash discounts, no insurance required
TrumpRx targets the “cash-pay” market — patients without insurance coverage, those hitting deductibles or facing high copays. Visitors enter their medication, location and pharmacy preference to unlock coupon codes redeemable nationwide. GoodRx powers the backend pricing integration, streamlining access without manufacturer websites or eligibility forms.
Key disclaimers: Discounts apply only to cash payments, not insurance deductibles or covered benefits. The site emphasizes “self-pay patients” and excludes government programs initially, though Medicaid integration looms. Trump highlighted “Most Favored Nation” pricing deals exempting participating companies from U.S. tariffs, pressuring Big Pharma into voluntary cuts.
Initial offerings span chronic conditions: diabetes (Ozempic), obesity (Wegovy, Zepbound), autoimmune (Xeljanz), menopause (Duavee), eczema (Eucrisa) and more. A FAQ promises “many more drugs coming soon,” signaling expansion.
White House hails ‘Big Pharma-gouging’ endgame
Trump framed the launch as populist warfare against pharmaceutical pricing. “Thanks to President Trump, the days of Big Pharma-gouging are over,” the website declares. Administration officials cited U.S. patients paying 2-4 times more than Canadians or Europeans for identical drugs, blaming PBMs, rebates and lack of price competition.
RFK Jr. positioned TrumpRx within broader reforms: “This is Phase One. Direct-to-consumer transparency forces real competition.” Dr. Oz demoed the site live, pulling up Ozempic at $346 monthly versus $1,086 list — a 68% cut. Pfizer’s Bourla committed 30+ drugs immediately, calling it “a win for patients and innovation.”
The event echoed Trump’s first-term “Most Favored Nation” executive order, revived after court blocks. Participating firms gain tariff exemptions; non-joiners face import scrutiny. Critics call it coercive; supporters hail market disruption.
Drug-by-drug savings spotlight
TrumpRx spotlights blockbuster discounts:
| Drug |
Use |
List Price (Monthly) |
TrumpRx Price |
Savings |
| Ozempic |
Diabetes/Weight Loss |
$1,086 |
$346 |
68% |
| Wegovy |
Obesity |
$1,349 |
$399 |
70% |
| Duavee |
Menopause |
$500+ |
$75 |
85% |
| Xeljanz |
Autoimmune |
$5,800 |
$1,200 |
79% |
| Eucrisa |
Eczema |
$700 |
$162 |
77% |
Fertility drugs drew praise: IVF medications, often $10,000+ per cycle, slash to accessible levels. “This is a big deal for families,” noted one analyst.
Pharma partners and expansion roadmap
Launch partners pledged aggressively:
- Pfizer: 30+ drugs, including menopause, autoimmune, bladder treatments.
- Novo Nordisk: GLP-1 leaders Ozempic/Wegovy at fraction of list.
- Eli Lilly: Zepbound, Orforglipron (pending FDA) at $346 monthly.
- AstraZeneca, EMD Serono: Oncology, fertility additions imminent.
Eleven more firms — undisclosed — integrate within months. GoodRx’s role ensures pharmacy ubiquity; Walgreens, CVS, independents participate.
Critics question scope, sustainability
Skeptics abound. Dr. Christina Madison called it “GoodRx-like” but centralized: “Patient assistance repackaged — helpful, not revolutionary.” AARP warned discounts skip insured patients, leaving 150 million unaffected. Pharma lobby PhRMA stressed R&D needs: “Voluntary cuts can’t replace innovation incentives.”
Democrats decried cash-only limits: “Helps uninsured, ignores working families with crappy insurance,” tweeted Sen. Elizabeth Warren. GoodRx affirmed partnership: “We host self-pay prices, integrate seamlessly.”
Legal watchers eye MFN revival: Biden-era courts struck similar rules; Trump 2.0 tests fresh ground. Early traffic crashed TrumpRx.gov temporarily, signaling demand.
Patient stories fuel populist pitch
White House spotlit real users:
- Sarah T., Ohio: Ozempic from $900 to $350 monthly — “Life-changing.”
- Mike R., Texas: IVF drugs halved — “Dreams affordable now.”
- Linda P., Florida: Duavee at $75 — “Menopause relief without bankruptcy.”
Trump touted 300 million potential beneficiaries: “Every American deserves medicine at fair prices.” RFK Jr. vowed Phase 2: insulin caps, PBM bans.
Timing ties to midterms, health care wars
Launch precedes 2026 midterms, where drug prices rank top voter concerns (72% per KFF). Gallup pegs affordability above inflation. Trump positions TrumpRx as 2024 promise kept: “I said I’d fix it — watch me deliver.” Polling shows 65% approval for direct discounts.
Globally, Canada/India parallel import threats loom if Pharma balks. EU praised transparency; WHO urged universality.
Tech behind TrumpRx: User-friendly disruption
Built on GoodRx infrastructure, TrumpRx offers geo-targeted pharmacy matching, mobile coupons, price comparisons. Spanish/English bilingual; ADA compliant. CMS integration teases Medicare expansion.
Beta testing yielded 92% redemption success; average savings $400 monthly per user. Site traffic hit 1M+ Thursday night.
Big Pharma’s reluctant embrace
Pfizer led buy-in: “Patients win, we innovate,” Bourla stated. Novo Nordisk followed, slashing GLP-1s amid Wegovy shortages. Eli Lilly timed with Zepbound; AstraZeneca eyes oncology next.
Non-participants risk tariffs, public backlash. Merck, J&J mum; analysts predict trickle joining by March.
What comes next for American drug prices
Phase 2 teases insulin at $35, EpiPens slashed, PBM rebate bans. Trump eyes Canada pharmacy flights if Pharma resists. RFK Jr. champions transparency laws mirroring Europe’s HTA systems.
TrumpRx.gov lives now — search, print, save. For 50 million uninsured and deductibled Americans, relief arrives. Scale remains question; impact, already real.